ARTA
GYRE icon

A.R.T. Advisors’s Gyre Therapeutics GYRE Stock Holding History

A.R.T. Advisors’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-2,930
Closed -$150K – 445
2019
Q4 		$150K Buy
2,930
+168
+6% +$7.04K 0.01% 1187
2019
Q3 		$102K Sell
2,762
-282
-9% -$15.2K 0.01% 1262
2019
Q2 		$168K Buy
3,044
+420
+16% +$26.2K 0.01% 1131
2019
Q1 		$160K Buy
2,624
+963
+58% +$61.9K 0.01% 1108
2018
Q4 		$98K Sell
1,661
-867
-34% -$63.9K 0.01% 1167
2018
Q3 		$204K Buy
+2,528
New +$200K 0.01% 1185
2017
Q1 		– Sell
-92
Closed -$6K – 1525
2016
Q4 		$6K Buy
+92
New +$8.28K ﹤0.01% 1256
2015
Q1 		– Sell
-40
Closed -$83K – 1522
2014
Q4 		$83K Buy
40
+9
+29% +$17.3K ﹤0.01% 1317
2014
Q3 		$60K Sell
31
-16
-34% -$39.6K ﹤0.01% 1235
2014
Q2 		$167K Buy
47
+5
+12% +$16.3K 0.01% 1169
2014
Q1 		$158K Buy
42
+20
+91% +$74K 0.01% 1184
2013
Q4 		$71K Sell
22
-17
-44% -$67K ﹤0.01% 1213
2013
Q3 		$162K Buy
+39
New +$157K 0.01% 1174

Other funds holding GYRE

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

A.R.T. Advisors's GYRE Position: Q1 2020 in Review

A.R.T. Advisors sold out of Gyre Therapeutics (GYRE) in Q1 2020, closing a stake of 2,930 shares — an estimated $150K sold.

A.R.T. Advisors first reported a position in GYRE in Q3 2013 and held it in 13 quarters. The position peaked at $204K in Q3 2018. 46 funds tracked by Wall St. Rank hold GYRE as of Q1 2020.

  • A.R.T. Advisors reported no remaining Gyre Therapeutics position as of Q1 2020 after selling out during the quarter.
  • A.R.T. Advisors sold 2,930 Gyre Therapeutics shares in Q1 2020, an estimated $150K.
  • A.R.T. Advisors first reported a position in Gyre Therapeutics in Q3 2013 and held it in 13 quarters.
  • A.R.T. Advisors's Gyre Therapeutics position peaked at $204K in Q3 2018.
  • 46 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q1 2020.

Based on A.R.T. Advisors's 13F filing for Q1 2020, filed 15 May 2020.